Philadelphia, PA, 22 October 2009 - After exposure to extreme life stresses, what distinguishes the individuals who do and do not develop posttraumatic stress disorder (PTSD)? A new study, published in the October 1st issue of Biological Psychiatry, suggests that it has something to do with the way that we control the activity of the prefrontal cortex, a brain region thought to orchestrate our thoughts and actions.
Researchers at the Mount Sinai School of Medicine examined women who had been the victims of violent sexual assault, some of whom developed PTSD and others who did not develop any serious emotional symptoms afterwards. Using a brain imaging technique, they evaluated the ability of these women to voluntarily modify their own responses to unpleasant emotional stimuli and found that it was the trauma history itself, not how well they endured this sort of trauma, that influenced their ability to dampen subsequent emotional responses.
Surprisingly, however, the ability of the subjects to amplify their emotional responses to unpleasant stimuli was related to psychological outcome after the sexual assault. The resilient individuals, that is, those who endured sexual assault without developing emotional symptoms, were able to enhance the activation of emotional brain circuitry in response to unpleasant stimuli more than either those with PTSD or healthy controls who had never experienced a serious sexual assault.
Corresponding author Dr. Antonia New explained the findings: "This raises the possibility that the ability to focus on negative emotions permits the engagement of cognitive strategies for extinguishing negative emotional responses, and that this ability might be related to resilience. This is important, since it has implications for how we might enhance resilience."
These findings suggest that exposure to extremely stressful situations may leave an "emotional scar" that may influence the capacity to be resilient to the impact of subsequent stressors, even when one does not develop PTSD. "These data seem to support an idea that has emerged from clinical descriptions of resilient people, i.e., that people who are resilient are able to be flexible in the way that they respond to changing emotional contexts. It would be helpful to know how we can enhance the flexible activation of these prefrontal cortex networks in people with compromised resilience," commented Dr. John Krystal, Editor of Biological Psychiatry.
Dr. New agrees, adding that "perhaps the enrichment of the broad capacity to tolerate negative emotional experiences might be helpful in promoting resilience. Further work needs to be done on whether the feature of this capacity that relates to resilience is about the ability to tolerate one's one responses, or whether it is the ability to respond distress in others."
Notes to Editors:
The article is "A Functional Magnetic Resonance Imaging Study of Deliberate Emotion Regulation in Resilience and Posttraumatic Stress Disorder" by Antonia S. New, Jin Fan, James W. Murrough, Xun Liu, Rachel E. Liebman, Kevin G. Guise, Cheuk Y. Tang, and Dennis S. Charney. All authors are affiliated with the Department of Psychiatry, Mount Sinai School of Medicine, New York, New York. Dr. New is also affiliated with the Mental Health Care Center, James J. Peters Veterans Affairs Medical Center, Bronx, New York. The article appears in Biological Psychiatry, Volume 66, Issue 7 (October 1, 2009), published by Elsevier.
The authors' disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D. is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available at http://journals.
Full text of the article mentioned above is available upon request. Contact Jayne M. Dawkins at firstname.lastname@example.org to obtain a copy or to schedule an interview.
About Biological Psychiatry
This international rapid-publication journal is the official journal of the Society of Biological Psychiatry. It covers a broad range of topics in psychiatric neuroscience and therapeutics. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and treatment of major neuropsychiatric disorders. Full-length and Brief Reports of novel results, Commentaries, Case Studies of unusual significance, and Correspondence and Comments judged to be of high impact to the field are published, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Concise Reviews and Editorials that focus on topics of current research and interest are also published rapidly.
Biological Psychiatry (www.sobp.org/journal) is ranked 4th out of the 101 Psychiatry titles and 14th out of 219 Neurosciences titles on the 2008 ISI Journal Citations Reports® published by Thomson Scientific.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including the Lancet (www.thelancet.com) and Cell (www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (www.sciencedirect.com), Scopus (www.scopus.com), Reaxys (www.reaxys.com), MD Consult (www.mdconsult.com) and Nursing Consult (www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (www.scival.com) and MEDai's Pinpoint Review (www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier (www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading publisher and information provider. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).